pharmaphorum

DECEMBER 24, 2020

The US National Institutes of Health said that the research it had co-funded used AI to transform a bacterial protein into a new research tool. It was led by researchers in the lab of Dr Lin Tian, principal investigator at the University of California Davis School of Medicine.

Development 77

Development Drugs Protein Genetic Engineering 77

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. About NVX-CoV2373.

Protein 52

Protein Vaccination Vaccine Immune Response 52

Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells.

Development 75

Development Drugs Manufacturing Immune Response 75

XTalks

MARCH 28, 2024

For CRC, treatment options that are targeting genetic mutations such as BRAF , KRAS and HER2 have been developed. Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment. Yang Liu and CFO Abid Ansari – Xtalks Life Science Podcast Ep.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

Drug Discovery World

JULY 5, 2023

For example, in CAR-T-cell therapy, scientists can take T-cells from a patient and ex vivo (outside the body) genetically engineer them to effectively target and kill cancerous cells, then infuse them back in to the patient. Of course, if a patient’s tumour does not have this protein, then this type of treatment won’t be effective.

Research 98

Research Protein Scientist Immune Response 98

pharmaphorum

MARCH 10, 2021

The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 The latest research is published in the New England Journal of Medicine. 1 mutations, as well as variants from the UK and South Africa.

Vaccination 66

Vaccination Vaccine Genetic Engineering Engineer 66

Drug Discovery World

NOVEMBER 17, 2022

The rapidly growing area of synthetic biology – including molecular biology, biotechnology, biophysics, and genetic engineering – is having a marked impact on the drug discovery landscape. For example, by engineering these synthetic cells to deliver medicines encapsulated in sub-compartments. .

Bacteria 52

Bacteria Engineer Gene Genetics 52

The Pharma Data

JUNE 1, 2022

. “The whole idea is if this molecule is not there, the mouse will do better, which means if you target this molecule, then humans should do better,” said co-senior study author Amal Amer, professor of microbial infection and immunity in The Ohio State University College of Medicine.

Immune Response 52

Immune Response Genetic Engineering Engineer Research 52

XTalks

AUGUST 17, 2020

protein-based biologics) and vaccine treatments. protein-based biologics) : are those which bind to specific components (i.e. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

JULY 27, 2021

Amgen’s R&D resources and its extensive clinical experience in immuno-oncology are ideally suited to applying and advancing Teneobio’s differentiated technologies and multispecific antibodies to deliver transformative medicines,” said Roland Buelow, Ph.D., chief executive officer of Teneobio.

Production 52

Production Antibody Sales Manufacturing 52

Drug Discovery World

JULY 22, 2022

An emerging area in the immuno-oncology field is a precision medicine approach in which HIS mice could be used to predict patient outcomes and determine if patient-derived TIL or ICIs are sufficient to eradicate tumours 11. MSCs have been traditionally used for regenerative medicine. After earning a B.A. References.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Gene splicing using nucleases is used to design gene therapeutics for various genetic disorders.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

Drug Discovery World

FEBRUARY 3, 2023

The clinical study The researchers developed VSV-SUDV using techniques that led to Ervebo, the VSV-EBOV vaccine that the European Medicines Agency and the US Food and Drug Administration approved in 2019 as the first vaccine for the prevention of Ebola virus disease.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Phil Jones, VP Discovery, RxBiologics, on: ‘Antibody discovery using the Galaxy library platform’.

Antibody 62

Antibody Engineer Protein Scientist 62

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. James Cooke, PhD, Associate Director, Bicycle Therapeutics, on: ‘Engineering bicyclic peptides for precision targeted medicine’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

SEPTEMBER 8, 2020

About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. These therapeutics are broadly classified into two categories, namely coding RNAs and non-coding RNAs.

RNA 40

RNA Protein Genetics Gene Expression 40

The Pharma Data

SEPTEMBER 8, 2020

(LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Cambridge, UK.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Drug Discovery World

SEPTEMBER 28, 2022

The encouraging study was led by Prof Ronit Satchi-Fainaro and PhD student Sabina Pozzi of the Sackler Faculty of Medicine at Tel Aviv University. Satchi-Fainaro and her team tried to inhibit the expression of the protein and its receptors in genetically engineered lab models and in 3D models of primary melanoma and brain metastases.

Research 52

Research Gene Editing Genetic Engineering Protein 52

pharmaphorum

JANUARY 10, 2022

It’s early days, but suggests Novartis sees potential for ensovibep in the medium to long term as a highly effective medicine that could be used to treat SARS-CoV-2 after it becomes an endemic infection.

Trials 52

Trials Drugs Antibody Genetic Engineering 52

Roots Analysis

FEBRUARY 15, 2022

Gene engineering based on recombination was pioneered in the mid-1990s; Currently, development of gene editing technologies has opened up the possibility of modifying genomic sequences in both eukaryotic and prokaryotic organisms. They also allow genetic material to be added, removed, or altered at particular locations in the genome.

Genome 52

Genome Genomics Gene Editing DNA 52

Drug Discovery World

MARCH 13, 2023

Between the 24 therapies already approved by the FDA 1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. Genetic Engineering & Biotechnology News. The cell and gene therapy (CGT) landscape has grown significantly in the past year. August 2020. April 4, 2022.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

Drug Discovery World

JANUARY 23, 2023

Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector. Single-cell RNA-sequencing of differentiating iPS cells reveals dynamic genetic effects on gene expression.

Gene Editing 52

Gene Editing Gene Engineer DNA 52